Atria Investments Inc lifted its holdings in iShares Floating Rate Bond ETF (BATS:FLOT – Free Report) by 53.7% during the ...

AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...

Overall survival at 3 years was 57.4% and 50.7% in the FLOT and preoperative-chemoradiotherapy groups, respectively, with a median follow-up of 55 months. Jens Hoeppner, MD, from Bielefeld ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

The School of the Art Institute of Chicago announced the appointment of Rob Flot as the next vice president and dean of ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...